Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients ...

New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...

产品概述球阀是一种重要的阀类，在石油化工、长输管线等领域有 应用。球阀的关闭件是一个带孔的球体（或部分球），球体随阀杆转动，实现阀门的开启或关闭。在各种阀门中，球阀的流动阻力zui小，全径球阀打开时，球体通道、阀体通道和连接管径相等并成 ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

三片式焊接球阀，304不锈钢三片式焊接球阀面议 浙江温州浙江米勒洁净设备科技有限公司实 2024-11-27询价 高压球阀 Q61N焊接式高压球阀￥500/件 上海上海上海意威阀门有限公司实 2023-10-02询价 高压焊接球阀Q21F￥100/只 上海上海上海丹况阀门有限公司实 2013-10-29询价 ...

Silexion Therapeutics (SLXN) announced new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. The findings ...

Quantum computing and artificial intelligence (AI) can be combined with classical computing methods to design and discover small-molecule candidates that target the cancer-driving KRAS protein, ...

A single systemic administration of SIL-204 maintained effective drug levels in rat plasma and tissues for over 56 days. SIL-204 inhibits key oncogenic KRAS mutations, including G12D, G12V, G12R, Q61H ...

在对KRAS成功研究的基础上，研究人员正在将他们的量子-经典混合模型应用于其他“不可成药”的蛋白。与KRAS类似，这些蛋白质通常很小，表面缺乏轮廓，使分子难以与之结合。研究小组还计划利用混合模型进一步对两款KRAS的苗头化合物展开进一步的优化设计，旨 ...

SIL-204 reduced tumor growth by ~50% and caused complete necrosis in ~50% of human pancreatic tumors in mice models with G12D mutations. A single systemic dose of SIL-204 sustained effective drug ...